Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest Revenue

Below are the small-cap diagnostic substances stocks on the NYSE and the NASDAQ in terms of revenue. The trailing-twelve-month revenue at Neogen (NASDAQ: NEOG ) is $225.21 million. Neogen's ROE for the same period is 10.59%. The trailing-twelve-month revenue at Abaxis (NASDAQ: ABAX ) is $188.77 million. Abaxis's PEG ratio